Free Practice Questions for Iraqi Board Clinical Pharmacy

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Iraqi Board for Medical Specializations (البورد العراقي — IBMS)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Exam Review

Key Facts: Iraqi Board Clinical Pharmacy Exam

IBMS / MOHESR

Governing Body & Ministry

Iraqi Board for Medical Specializations

4 Years

Residency Training Duration

IBMS Curriculum 2025

70%

Pass Criteria per Part

IBMS Examination Regulations

100 MCQs

Paper 1 Question Count

IBMS Exam Architecture

The Iraqi Board of Clinical Pharmacy (IBMS/MOHESR) credential requires a 4-year residency assessed by the Year 1 Primary Exam (100 MCQs, 70% pass) and the Year 4 Comprehensive Board Examination, which features Theory (Paper 1: 100 MCQs, 2.5 hours; Paper 2: 10 short clinical essay cases) and Clinical components (OSCE + 10 OSBE slides). Passing requires 70% in each part, with a maximum of 3 attempts permitted. This independent 100-question practice bank supports preparation for the theoretical written scope of Paper 1; it is not a clinical OSCE/OSBE simulation or a substitute for accredited residency training.

Sample Iraqi Board Clinical Pharmacy Practice Questions

Try these sample questions to review concepts for the Iraqi Board Clinical Pharmacy exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1According to the updated consensus guidelines for therapeutic monitoring of vancomycin in serious MRSA infections, which pharmacokinetic/pharmacodynamic (PK/PD) parameter is the preferred predictor of efficacy and safety?

A.Trough serum concentration maintained between 15 and 20 mcg/mL

B.Area under the curve to minimum inhibitory concentration ratio (AUC24/MIC) of 400 to 600 mg*h/L

C.Peak serum concentration maintained between 30 and 40 mcg/mL

D.Time above the minimum inhibitory concentration (T > MIC) exceeding 50% of the dosing interval

Explanation: The revised consensus guidelines (ASHP/IDSA/PIDS/SIDP) recommend an individualized AUC24/MIC (BMD) target of 400 to 600 mg*h/L (assuming an MIC of 1 mg/L) for serious MRSA infections. Trough-only monitoring (15-20 mcg/mL) is no longer recommended because it is a poor surrogate for AUC and is associated with increased acute kidney injury without improved clinical efficacy.

2Which pharmacological property provides the primary scientific rationale for once-daily (extended-interval) high-dose aminoglycoside therapy compared to conventional multiple-daily dosing in Gram-negative sepsis?

A.Time-dependent bactericidal killing with no post-antibiotic effect

B.Concentration-dependent bactericidal killing and a prolonged post-antibiotic effect (PAE)

C.Decreased renal cortical tissue accumulation during prolonged high peak levels

D.Enhanced hepatic clearance that reduces systemic circulating toxicity

Explanation: Aminoglycosides exhibit concentration-dependent bactericidal activity (optimal Cmax/MIC ratio of 8 to 10) and a substantial post-antibiotic effect (PAE) lasting several hours against Gram-negative bacilli. Once-daily dosing achieves higher peak concentrations to maximize killing and allows drug concentrations to fall below toxic thresholds for a prolonged interval, saturating renal uptake mechanisms and reducing nephrotoxicity and ototoxicity.

3A 52-year-old male with focal epilepsy has a steady-state total phenytoin serum concentration of 11 mcg/mL on 300 mg/day orally. The clinician increases the dose to 400 mg/day (a 33% increase). Two weeks later, the patient presents with ataxia, nystagmus, and a phenytoin concentration of 28 mcg/mL. What pharmacokinetic principle explains this disproportionate rise?

A.First-order linear elimination with rapid gastrointestinal absorption

B.Non-linear Michaelis-Menten saturation kinetics of hepatic CYP2C9/CYP2C19 metabolism

C.Decreased volume of distribution resulting from displacement of albumin binding

D.Auto-inhibition of intestinal P-glycoprotein efflux transporters

Explanation: Phenytoin exhibits capacity-limited, non-linear (Michaelis-Menten) elimination kinetics at therapeutic concentrations. As the hepatic metabolizing enzymes (predominantly CYP2C9 and CYP2C19) approach saturation (Vm), clearance decreases and small dosage increases result in disproportionately large, unpredictable increases in steady-state serum concentrations, precipitating clinical toxicity.

4A 65-year-old female patient (weight: 60 kg, height: 162 cm) is admitted with urosepsis. Her serum creatinine is stable at 1.5 mg/dL. Using the Cockcroft-Gault equation, which value is closest to her estimated creatinine clearance (CrCl)?

A.42 mL/min

B.35 mL/min

C.48 mL/min

D.28 mL/min

Explanation: Cockcroft-Gault formula for females: CrCl = [(140 - Age) * Weight (kg) * 0.85] / [72 * SCr (mg/dL)]. Substituting the patient's values: [(140 - 65) * 60 * 0.85] / [72 * 1.5] = [75 * 60 * 0.85] / 108 = 3825 / 108 = 35.4 mL/min. This falls closest to 35 mL/min.

5In patients with heart failure with reduced ejection fraction (HFrEF) receiving digoxin, what is the established target serum concentration range associated with reduced hospitalizations without increased all-cause mortality?

A.0.5 to 0.9 ng/mL

B.1.2 to 2.0 ng/mL

C.2.0 to 2.5 ng/mL

D.0.1 to 0.4 ng/mL

Explanation: Post-hoc analyses of the Digitalis Investigation Group (DIG) trial and contemporary HF guidelines establish that serum digoxin concentrations of 0.5 to 0.9 ng/mL optimize clinical outcomes by reducing heart failure hospitalizations without increasing mortality. Concentrations >= 1.0 to 1.2 ng/mL provide no additional inotropic benefit and are associated with increased all-cause mortality, particularly in women and elderly patients.

6A 58-year-old male is receiving intravenous gentamicin combined with ampicillin for Enterococcus faecalis native valve infective endocarditis. Which dosing regimen and target peak/trough serum concentrations are recommended for synergistic therapy in this setting?

A.Extended-interval 5 to 7 mg/kg every 24 hours targeting peak 16-24 mcg/mL and trough < 1 mcg/mL

B.Conventional low-dose 1 mg/kg every 8 hours targeting peak 3-4 mcg/mL and trough < 1 mcg/mL

C.Continuous infusion targeting steady-state concentration of 5-8 mcg/mL

D.High-dose divided 3 mg/kg every 8 hours targeting peak 8-10 mcg/mL and trough < 2 mcg/mL

Explanation: For synergistic treatment of enterococcal endocarditis, low-dose conventional gentamicin (1 mg/kg every 8 hours or 3 mg/kg divided daily) is recommended, targeting a peak serum concentration of 3 to 4 mcg/mL and a trough concentration of < 1 mcg/mL. High-dose once-daily (extended-interval) aminoglycosides are not recommended for enterococcal endocarditis synergy due to lack of clinical trial evidence.

7A 60-year-old chronic smoker with severe COPD on oral theophylline 400 mg twice daily has a stable serum level of 12 mcg/mL. He is admitted to the hospital, completely stops smoking tobacco, and is maintained on the same theophylline dose. What pharmacokinetic alteration is expected within 1 to 2 weeks of smoking cessation?

A.Induction of CYP2E1 leading to decreased serum theophylline concentrations

B.Loss of CYP1A2 induction leading to decreased theophylline clearance and increased toxicity risk

C.Decreased renal tubular reabsorption leading to subtherapeutic theophylline concentrations

D.Increased volume of distribution requiring a dosage increase

Explanation: Polycyclic aromatic hydrocarbons in tobacco smoke induce hepatic CYP1A2, increasing theophylline clearance by 50% to 100%. When smoking ceases, the inductive stimulus disappears over 1 to 2 weeks, resulting in a progressive decline in CYP1A2 clearance. Maintaining the same dosage leads to theophylline accumulation and toxic serum concentrations (> 20 mcg/mL), causing arrhythmias, nausea, and seizures.

8A 45-year-old female with nephrotic syndrome has a total serum phenytoin concentration of 7 mcg/mL and a serum albumin of 2.0 g/dL (normal: 4.0-5.0 g/dL), with normal renal function. Using the Winter-Tozer equation, what is her estimated normalized (corrected) total phenytoin concentration?

A.14 mcg/mL

B.7 mcg/mL

C.21 mcg/mL

D.10.5 mcg/mL

Explanation: The Winter-Tozer equation for patients with hypoalbuminemia and normal renal function is: C_corrected = C_observed / [(0.2 * Albumin) + 0.1]. Substituting: C_corrected = 7 / [(0.2 * 2.0) + 0.1] = 7 / [0.4 + 0.1] = 7 / 0.5 = 14 mcg/mL. While the measured total level (7 mcg/mL) appears subtherapeutic, the free active phenytoin level corresponds to a normalized total level of 14 mcg/mL, which is well within the therapeutic range (10-20 mcg/mL).

9A patient undergoing percutaneous coronary intervention (PCI) with drug-eluting stent placement is identified as a CYP2C19 poor metabolizer (*2/*2 genotype). What is the clinical implication of this pharmacogenomic finding for clopidogrel therapy?

A.Increased active metabolite formation resulting in high bleeding risk

B.Diminished active metabolite formation resulting in increased risk of stent thrombosis and major adverse cardiovascular events (MACE)

C.Enhanced renal tubular clearance of clopidogrel requiring higher doses

D.No alteration in efficacy because clopidogrel does not require hepatic activation

Explanation: Clopidogrel is an inactive prodrug that requires a two-step hepatic bioactivation process, primarily mediated by CYP2C19. Individuals carrying loss-of-function alleles (*2 or *3) produce significantly less active thiol metabolite, leading to inadequate platelet inhibition, clopidogrel resistance, and elevated risk of stent thrombosis and recurrent ischemic events. CPIC guidelines recommend an alternative antiplatelet agent (prasugrel or ticagrelor) in CYP2C19 poor and intermediate metabolizers.

10A 70 kg critically ill patient receiving IV vancomycin 1250 mg every 12 hours has two steady-state serum levels drawn during the same dosing interval: C1 = 28 mcg/mL (drawn 2 hours post-infusion) and C2 = 14 mcg/mL (drawn 8 hours post-infusion, exactly 6 hours after C1). What is the elimination rate constant (kel) and the estimated half-life (t1/2) for this patient?

A.kel = 0.116 h^-1; t1/2 = 6.0 hours

B.kel = 0.058 h^-1; t1/2 = 12.0 hours

C.kel = 0.231 h^-1; t1/2 = 3.0 hours

D.kel = 0.029 h^-1; t1/2 = 24.0 hours

Explanation: Elimination rate constant kel = [ln(C1) - ln(C2)] / delta_t = [ln(28) - ln(14)] / 6 = [3.332 - 2.639] / 6 = 0.693 / 6 = 0.1155 h^-1 (rounded to 0.116 h^-1). The half-life is t1/2 = 0.693 / kel = 0.693 / 0.1155 = 6.0 hours. Notice that the concentration fell by exactly 50% (from 28 to 14 mcg/mL) over 6 hours, directly demonstrating that the half-life is 6.0 hours.

About the Iraqi Board Clinical Pharmacy Exam

The Fellowship of the Iraqi Board for Medical Specializations in Clinical Pharmacy (F.I.B.M.S.) is the premier clinical pharmacy specialty qualification in Iraq, awarded by the Iraqi Board for Medical Specializations (IBMS) under the Ministry of Higher Education and Scientific Research (MOHESR). The 4-year curriculum provides advanced hospital residency training spanning internal medicine, surgery, obstetrics/gynecology, pediatrics, hematology/oncology, coronary care, renal dialysis and kidney transplantation, bone marrow transplantation, clinical pharmacokinetics and therapeutic drug monitoring (TDM), pulmonary and adult intensive care, neonatology, and clinical toxicology. Important disclosure: The complete FIBMS exit credential requires 4 years of supervised clinical rotations, research thesis defense and publication, Theory Paper 2 (10 short clinical assay cases), and clinical OSCE/OSBE stations, which multiple-choice questions cannot simulate. This 100-question multiple-choice practice bank is an independent educational tool designed to reinforce theoretical knowledge and pharmacotherapeutic decision-making for Paper 1 (100 MCQs). It is not an official IBMS examination, does not provide clinical OSCE stations, and is not a substitute for formal accredited clinical residency training.

Exam sponsor: Scientific Council of Clinical Pharmacy, Iraqi Board for Medical Specializations (المجلس العراقي للاختصاصات الطبية — المجلس العلمي للصيدلة السريرية). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Iraqi Board in Clinical Pharmacy is a four-year clinical specialty residency governed by the Scientific Council of Clinical Pharmacy under the Iraqi Board for Medical Specializations (IBMS) and MOHESR. The assessment pathway comprises two primary examination milestones: 1) The Primary Examination, administered at the conclusion of Year 1, consisting of a written 100-MCQ examination covering core clinical medicine, surgery, obstetrics, pediatrics, and clinical sciences (pass mark 70%). 2) The Comprehensive Board Examination, sat at the end of Year 4 following satisfactory completion of all rotations, clinical logbook evaluation, and successful defense and publication of a research thesis. The Comprehensive Board Examination is divided into: A) Theory Examination, consisting of Paper 1 (a written 100-MCQ exam, 2.5 hours duration) and Paper 2 (a written short assay exam featuring 10 clinical cases); and B) Clinical Examination, consisting of an Objective Structured Clinical Examination (OSCE) and an Objective Structured Bedside/Slide Examination (OSBE) featuring 10 clinical-based slides. Passing requires a minimum score of 70% in each individual part. Candidates are granted a maximum of three attempts per part before dismissal.

Time Limit

2.5 hours (150 minutes)

Passing Score

70% in each part

Exam / Certification Fees

Prescribed by Iraqi Board for Medical Specializations / MOHESR regulatory bylaws

Exam sponsor website

Reported exam pass rate: 70% pass mark per part. Candidates must achieve at least 70% in each component of the comprehensive examination: Theory Paper 1, Theory Paper 2, and the Clinical OSCE/OSBE. A maximum of 3 attempts is permitted per part. This describes exam candidates, not OpenExamPrep users or results from using our resources. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

20%

Applied Pharmacokinetics, TDM & Pharmacogenomics

Vancomycin AUC/MIC ratio calculations and trough monitoring, aminoglycoside once-daily and synergy pharmacokinetics, non-linear phenytoin saturation kinetics, theophylline clearance, digoxin dosing, and CYP450 pharmacogenomics.

25%

Cardiovascular & Renal Pharmacotherapy

Guideline-directed medical therapy for HFrEF and HFpEF, acute coronary syndrome antithrombotic therapy, stroke prevention in atrial fibrillation with DOACs and warfarin, management of hypertensive urgencies and emergencies, and dosing in acute kidney injury and end-stage renal disease.

20%

Infectious Diseases & Antimicrobial Stewardship

Empiric antimicrobial selection in sepsis and healthcare-associated infections, therapy for resistant pathogens (MRSA, VRE, ESBL, CRE, and MDR Pseudomonas aeruginosa), invasive fungal infections, viral therapeutics, and hospital stewardship interventions.

20%

Internal Medicine Pharmacotherapy

Comprehensive pharmacotherapy across endocrinology (DKA/HHS, type 1 and type 2 diabetes), gastroenterology and hepatology (cirrhotic ascites, variceal hemorrhage, spontaneous bacterial peritonitis), pulmonary medicine (asthma and COPD), neurology (status epilepticus and chronic seizure management), and rheumatology.

15%

Oncology, Critical Care & Patient Safety

Antineoplastic protocols, chemotherapy toxicity mitigation (anthracyclines, cisplatin, high-dose methotrexate), hemodynamic support and vasopressors in septic shock, adverse drug reaction causality assessment, and inpatient medication reconciliation.

Preparing for the Iraqi Board Clinical Pharmacy Exam

What You Need to Know

Passing score: 70% in each part
Assessment: The Iraqi Board in Clinical Pharmacy is a four-year clinical specialty residency governed by the Scientific Council of Clinical Pharmacy under the Iraqi Board for Medical Specializations (IBMS) and MOHESR. The assessment pathway comprises two primary examination milestones: 1) The Primary Examination, administered at the conclusion of Year 1, consisting of a written 100-MCQ examination covering core clinical medicine, surgery, obstetrics, pediatrics, and clinical sciences (pass mark 70%). 2) The Comprehensive Board Examination, sat at the end of Year 4 following satisfactory completion of all rotations, clinical logbook evaluation, and successful defense and publication of a research thesis. The Comprehensive Board Examination is divided into: A) Theory Examination, consisting of Paper 1 (a written 100-MCQ exam, 2.5 hours duration) and Paper 2 (a written short assay exam featuring 10 clinical cases); and B) Clinical Examination, consisting of an Objective Structured Clinical Examination (OSCE) and an Objective Structured Bedside/Slide Examination (OSBE) featuring 10 clinical-based slides. Passing requires a minimum score of 70% in each individual part. Candidates are granted a maximum of three attempts per part before dismissal.
Time limit: 2.5 hours (150 minutes)
Exam / certification fees: Prescribed by Iraqi Board for Medical Specializations / MOHESR regulatory bylaws Official sources

Using Our Practice Resources

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Iraqi Board Clinical Pharmacy: Suggested Study Strategy

1Master clinical pharmacokinetics calculations: practice vancomycin AUC/MIC trapezoidal and first-order equations, Cockcroft-Gault creatinine clearance determinations, aminoglycoside Hartford nomograms, and non-linear Michaelis-Menten phenytoin adjustments.

2Thoroughly review cardiovascular guidelines: understand GDMT initiation and titration in heart failure (ARNI/ACEi, beta-blockers, MRAs, SGLT2i), secondary prevention post-ACS, and DOAC renal dosing cutoffs in atrial fibrillation.

3Focus on antimicrobial spectrum and resistance mechanisms: memorize empiric regimens for hospital-acquired pneumonia, sepsis, and neutropenic fever, as well as target therapies for MRSA, ESBL producers, CRE, and Pseudomonas aeruginosa.

4Review critical care and oncology supportive care: master vasopressor receptor pharmacology in septic shock, high-dose methotrexate leucovorin rescue protocols, and rasburicase indications in tumor lysis syndrome.

5Integrate internal medicine pharmacotherapy: practice case-based problem solving for DKA/HHS fluid and insulin protocols, status epilepticus staged management, and cirrhosis complications (variceal hemorrhage prophylaxis and SBP treatment).

Frequently Asked Questions

What is the governing authority and credential awarded by the Iraqi Board in Clinical Pharmacy?

The program is directed by the Scientific Council of Clinical Pharmacy under the Iraqi Board for Medical Specializations (IBMS / المجلس العراقي للاختصاصات الطبية), functioning under the Ministry of Higher Education and Scientific Research (MOHESR). Graduates who successfully complete the 4-year residency, defend their thesis, and pass all written and clinical examinations receive the Fellowship of the Iraqi Board for Medical Specializations (F.I.B.M.S.) in Clinical Pharmacy, qualifying them as Clinical Pharmacy Specialists.

What is the examination structure of the Comprehensive Board Examination?

The final Comprehensive Board Examination at the end of Year 4 consists of two main divisions: A) Theory Examination, which includes Paper 1 (a written 100-MCQ exam lasting 2.5 hours) and Paper 2 (a written short assay exam containing 10 clinical case scenarios); and B) Clinical Examination, which includes an Objective Structured Clinical Examination (OSCE) and an Objective Structured Bedside/Slide Examination (OSBE) featuring 10 clinical slide cases. Candidates must achieve a passing grade of at least 70% in each part.

What are the passing scores and retake policies for the Iraqi Board in Clinical Pharmacy?

Candidates must achieve a minimum score of 70% in each individual component of the examination (Primary exam at end of Year 1; Comprehensive Theory Paper 1, Theory Paper 2, and Clinical OSCE/OSBE at end of Year 4). According to official IBMS regulations, candidates are permitted a maximum of three attempts per part. Candidates who fail to pass within three attempts are subject to dismissal from the program.

In what language are the Iraqi Board clinical pharmacy examinations administered?

The Iraqi Board for Medical Specializations publishes this council's curriculum, syllabus and reference list in English, and English-language proficiency appears among the admission requirements set by the Ministry. The council's published curriculum does not, however, contain any statement of the language in which the examination papers themselves are set, so no language of assessment is asserted here. This site is an independent English-language study resource and is not affiliated with, endorsed by, or connected to the Iraqi Board for Medical Specializations; candidates should confirm the language of their sitting directly with their Scientific Council.

Does this 100-question practice bank simulate the clinical OSCE or replace residency training?

No. The Iraqi Board in Clinical Pharmacy requires four full years of rigorous hospital residency training, logbook completion, original research dissertation defense, Paper 2 short essay clinical cases, and hands-on OSCE/OSBE clinical stations. This independent 100-question multiple-choice practice bank is designed specifically to test and reinforce theoretical pharmacotherapy and clinical pharmacokinetic concepts for Paper 1; it does not simulate the clinical OSCE/OSBE and does not substitute for accredited residency training.

Free Practice Questions for Iraqi Board Clinical Pharmacy

Explore More Iraqi Board for Medical Specializations (البورد العراقي — IBMS)

Iraqi Board of Internal Medicine Part 1 & 2 Written Exams (FIBMS)

Iraqi Board of Anesthesia & Intensive Care Part 1 & 2 Written Exams (FIBMS)

Iraqi Board of Cardiology Part 1 & 2 Written Exams (FIBMS)

Iraqi Board of Dermatology & Venereology Part 1 & 2 Written Exams (FIBMS)

Iraqi Board of Diagnostic Radiology Part 1 & 2 Written Exams (FIBMS)

Iraqi Board of Emergency Medicine Part 1 & 2 Written Exams (FIBMS)